Therapeutic approaches to patients with hypereosinophilic syndromes

Seminars in Hematology

Volumn 49, Issue 2, 2012, Pages 160-170

  Simon, Hans Uwe ^a   Klion, Amy ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; ANTIDEPRESSANT AGENT; ANTITHROMBOCYTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CORTICOSTEROID; CYANOCOBALAMIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DASATINIB; IMATINIB; IMMUNOGLOBULIN M ANTIBODY; INTERLEUKIN 3; INTERLEUKIN 5; IVERMECTIN; LOW MOLECULAR WEIGHT HEPARIN; MEPOLIZUMAB; METHOTREXATE; MIDOSTAURIN; NILOTINIB; PREDNISONE; SORAFENIB; TROPONIN; VITAMIN D; WARFARIN;

ANGIONEUROTIC EDEMA; ANTICOAGULATION; ARTICLE; BONE MARROW EXAMINATION; BONE SCINTISCANNING; CATARACT; CELL CLONE; CELL POPULATION; CELL SURVIVAL; CHURG STRAUSS SYNDROME; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL FEATURE; CORTICOSTEROID THERAPY; CYTOKINE PRODUCTION; DEPRESSION; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE CONTROL; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; ECHOCARDIOGRAPHY; EOSINOPHIL COUNT; EOSINOPHILIA; EOSINOPHILIC GASTROINTESTINAL DISORDER; FIP1L1 PDGFRA GENE; FUSION GENE; GENE MUTATION; GLAUCOMA; HEART MUSCLE FIBROSIS; HEART MUSCLE NECROSIS; HELMINTHIASIS; HUMAN; HYPEREOSINOPHILIC SYNDROME; HYPERTENSION; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION PREVENTION; LOEFFLER PNEUMONIA; LOW DRUG DOSE; MAINTENANCE DRUG DOSE; MAINTENANCE THERAPY; MOLECULAR DYNAMICS; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; MYOPATHY; OSTEOPOROSIS; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTOSIS; POINT MUTATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RELAPSE; SIGNAL TRANSDUCTION; STRONGYLOIDES; STRONGYLOIDIASIS; T LYMPHOCYTE; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION; WELLS SYNDROME;

DRUG HYPERSENSITIVITY; ENDOMYOCARDIAL FIBROSIS; HELMINTHIASIS; HUMANS; HYPEREOSINOPHILIC SYNDROME; THROMBOEMBOLISM;

EID: 84858754369     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2012.01.002     Document Type: Article

References (58)

1. Simon H.U., Rothenberg M.E., Bochner B.S., et al. Refining the definition of hypereosinophilic syndrome. J Allergy Clin Immunol 2010, 126:45-49.
2. Tefferi A., Vardiman J.W. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostics. Leukemia 2008, 22:14-22.
3. Valent P, Klion AD, Horny H, et al. Contemporary consensus on criteria and classification of eosinophil disorders and related syndromes. J Allergy Clin Immunol. In press.
4. Pardanani A., Reeder T., Porrata L.F., et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood 2003, 101:3391-3397.
5. Klion A.D., Noel P., Akin C., et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003, 101:4660-4666.
6. Pitini V., Arrigo C., Azzarello D., et al. Serum concentration of cardiac troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes. Blood 2003, 102:3456-3457.
7. Robyn J., Noel P., Wlodarska I., et al. Imatinib-responsive hypereosinophilia in a patient with B cell ALL. Leuk Lymphoma 2004, 45:2497-2501.
8. Nutman T.B., Miller K.D., Mulligan M., Ottesen E.A. Loa loa infection in temporary residents of endemic regions: recognition of a hyperresponsive syndrome with characteristic clinical manifestations. J Infect Dis 1986, 154:10-18.
9. Ogbogu P.U., Bochner B.S., Butterfield J.H., et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol 2009, 124:1319-1325.
10. Cools J., DeAngelo D.J., Gotlib J., et al. A novel tyrosine kinase created by the fusion of the PDGFRA and FIP1L1 genes is a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003, 348:1201-1214.
11. Rothenberg M.E., Klion A.D., Roufosse F.E., et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 2008, 358:1215-1228.
12. Ramanathan R., Nutman T. Strongyloides stercoralis infection in the immunocompromised host. Curr Infect Dis Rep 2008, 10:105-110.
13. Klion A.D., Law M.A., Riemenschneider W., et al. Familial eosinophilia: a benign disorder?. Blood 2004, 103:4050-4055.
14. Pardanani A., Brockman S.R., Paternoster S.F., et al. FIP1L1/PDGFRA fusion: prevalence and clinicopathologic correlates in 89 patients with moderate to severe eosinophilia. Blood 2004, 104:3038-3045.
15. Baccarani M., Cilloni D., Rondoni M., et al. The efficacy of imatinib in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica 2007, 92:1173-1179.
16. Klion A.D., Robyn J., Akin C., et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 2004, 103:473-478.
17. Rotoli B., Catalano L., Galderisi M., et al. Rapid reversion of Loeffler's endocarditis by imatinib in early stage clonal hypereosinophilic syndrome. Leuk Lymphoma 2004, 45:2503-2507.
18. Tefferi A., Pardanani A. Imatinib treatment-induced cardiomyopathy in hypereosinophilic syndrome. Blood 2003, 102:3456-3457.
19. Helbig G., Stella-Holowiecka B., Majewski M., et al. A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients. Br J Haematol 2008, 141:200-204.
20. Jovanovic J.V., Score J., Waghorn K., et al. Low-dose imatinib mesylate leads to rapid induction on major molecular repsonse and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 2007, 109:4635-4640.
21. Salemi S., Yousefi S., Simon D., et al. A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome. Allergy 2009, 64:913-918.
22. Simon D., Salemi S., Yousefi S., SImon H.U. Primary resistance to imatinib in Fip1-like 1-platelet-derived growth factor receptor alpha-positive eosinophilic leukemia. J Allergy Clin Immunol 2008, 121:1054-1056.
23. Klion A.D., Robyn J., Maric I., et al. Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing. Blood 2007, 110:3552-3556.
24. von Bubnoff N., Gorantla S.P., Engh R.A., et al. The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro. Oncogene 2011, 30:933-943.
25. Tabouret E., Charbonnier A., Mozziconacci M.J., Ivanov V. Low-dose nilotinib can maintain complete molecular remission in FIP1L1/PDGFRA-positive hypereosinophilic syndrome. Leuk Res 2011, 35:136.
26. Lierman E., Michaux L., Beullens E., et al. FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T6741 eosinophilic leukemia with single agent sorafenib. Leukemia 2009, 23:845-851.
27. Ikezoe T., Togitani K., Tasaka T., Nishioka C., Yokoyama A. Successful treatment of imatinib-resistant hypereosinophilic syndrome with nilotinib. Leuk Res 2010, 34:e200-e201.
28. Imagawa J., Harada Y., Yoshida T., et al. Successful treatment with low-dose dasatinib in a patient with chronic eosinophilic leukemia intolerant to imatinib. Rinsho Ketsueki 2011, 52:546-550.
29. Halaburda K., Prejzner W., Szatkowski D., Limon J., Hellman A. Allogeneic bone marrow transplantation for hypereosinophilic syndrome: long-term follow-up with eradication of FIP1L1-PDFGRA fusion transcript. Bone Marrow Transplant 2006, 38:319-320.
30. Ueno N.T., Anagnostopoulos A., Rondon G., et al. Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome. Br J Haematol 2002, 119:131-134.
31. Dahabreh I.J., Giannouli S., Zoi K., Loukopoulos D., Voulgarelis M. Hypereosinophilic syndrome: another face of janus. Leuk Res 2008, 32:1483-1485.
32. Helbig G., Majewski M., Wieczorkiewicz A., et al. Screening for JAK2 V617F point mutation in patient with hypereosinophilic syndrome- in repsonse to 'Hypereosinophilic syndrome: another face of janus?" by Dahabreh et al. published in Leukemia Research, in press. Leuk Res 2009, 33:e1-e2.
33. Butterfield J.H. Success of short-term, higher-dose imatinib mesylate to induce clinical response in FIP1L1-PDGFRalpha-negative hypereosinophilic syndrome. Leuk Res 2009, 33:1127-1129.
34. Masi A.T., Hunder G.G., Lie J.T., et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990, 33:1094-1100.
35. Dunogue B., Pagnoux C., Guillevin L. Churg-Strauss syndrome: clinical symptoms, complementary investigations, prognosis and outcome, and treatment. Semin Resp Crit Care Med 2011, 32:298-309.
36. Metzler C., Schnabel A., Gross W.L., Hellmich B. A phase II study of interferon-alpha for the treatment of refractory Churg-Strauss syndrome. Clin Exp Rheum 2008, 26:S35-S40.
37. Kim S., Marigowda G., Oren E., Israel E., Wechsler M.E. Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol 2010, 125:1336-1343.
38. Simon H.U., Plotz S.G., Dummer R., Blaser K. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 1999, 341:1112-1120.
39. Schandene L., Roufosse F., de Lavareille A., et al. Interferon alpha prevents spontaneous apoptosis of clonal Th2 cells associated with chronic hypereosinophilia. Blood 2000, 96:4285-4292.
40. Pitini V., Teti D., Arrigo C., Righi M. Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome with abnormal T cells: a case report. Br J Haematol 2004, 127:477.
41. Roufosse F., de Lavareille A., Schandene L., et al. Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome. J Allergy Clin Immunol 2010, 126:828-835.
42. Burbury K., Chew L.P., Westerman D., Catalano A., Seymour J.F. Concomitant FIP1L1-PDGFRA fusion gene and T cell-clonality in a case of chronic eosinophilic leukemia with clonal evolution and an incomplete response to imatinib. Leuk Lymphoma 2011, 52:335-338.
43. + T-cell clones associated with the lymphocytic variant of hypereosinophilic syndrome. Haematologica 2005, 90:753-765.
44. Weller P.F., Bubley G.J. The idiopathic hypereosinophilic syndrome. Blood 1994, 83:2759-2779.
45. Gleich G.J., Schroeter A.L., Marcoux J.P., Sach M.I., O'Connell E.J., Kohler P.F. Episodic angioedema associated with eosinophilia. N Engl J Med 1984, 310:1621-1626.
46. Morgan S.J., Prince H.M., Westerman D.A., McCormack C., Glaspole I. Clonal T-helper lymphocytes and elevated IL-5 levels in episodic angioedema and eosinophilia (Gleich's syndrome). Leuk Lymphoma 2003, 44:1623-1625.
47. Ribi C., Cohen P., Pagnoux C., et al. Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. Arthritis Rheum 2008, 58:586-594.
48. Bourgarit A., Le Toumelin P., Pagnoux C., et al. Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: a retrospective analysis of causes and factors predictive of mortality based on 595 patients. Medicine (Baltimore) 2005, 84:323-330.
49. Harley J.B., Fauci A.S., Gralnick H.R. Noncardiovascular findings associated with heart disease in the idiopathic hypereosinophilic syndrome. Am J Cardiol 1983, 52:321-324.
50. Spry C.J., Davies J., Tai P.C., Olsen E.G., Oakley C.M., Goodwin J.F. Clinical features of fifteen patients with the hypereosinophilic syndrome. Q J Med 1983, 52:1-22.
51. Slungaard A., Vercellotti G.M., Tran T., Gleich G.J., Key N.S. Eosinophil cationic granule proteins impair thrombomodulin function. A potential mechanism for thromboembolism in hypereosinophilic heart disease. J Clin Invest 1993, 91:1721-1730.
52. Wang J.G., Mahmud S.A., Thompson J.A., Geng J.G., Key N.S., Slungaard A. The principal eosinophil peroxidase product, HOSCN, is a uniquely potent phagocyte oxidant inducer of endothelial cell tissue factor activity: a potential mechanism for thrombosis in eosinophilic inflammatory states. Blood 2006, 107:558-565.
53. Moosbauer C., Morgenstern E., Cuvelier S.L., et al. Eosinophils are a major intravascular location for tissue factor storage and exposure. Blood 2007, 109:995-1002.
54. Swartz J.M., Bystrom J., Dyer K.D., Nitto T., Wynn T.A., Rosenberg H.F. Plasminogen activator inhibitor-2 (PAI-2) in eosinophilic leukocytes. J Leukoc Biol 2004, 76:812-819.
55. Moore P.M., Harley J.B., Fauci A.S. Neurologic dysfunction in the idiopathic hypereosinophilic syndrome. Ann Intern Med 1985, 102:109-114.
56. Schulman H., Hertzog L., Zirkin H., Hertzanu Y. Cerebral sinovenous thrombosis in the idiopathic hypereosinophilic syndrome in childhood. Pediatr Radiol 1999, 29:595-597.
57. Roe M.T., Ohman M. A new era in secondary prevention after acute coronary syndrome. N Engl J Med 2012, 366:95-97.
58. American College of Rheumatology Task Force on Osteoporosis Guidelines. Arthritis Rheum 1996, 39:1791-1801. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis.